These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Targeting mutant p53 through the mevalonate pathway. Freed-Pastor W; Prives C Nat Cell Biol; 2016 Oct; 18(11):1122-1124. PubMed ID: 27784901 [TBL] [Abstract][Full Text] [Related]
28. Tumor-suppressor p53: implications for tumor development and prognosis. Kirsch DG; Kastan MB J Clin Oncol; 1998 Sep; 16(9):3158-68. PubMed ID: 9738588 [TBL] [Abstract][Full Text] [Related]
29. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Flores ER; Sengupta S; Miller JB; Newman JJ; Bronson R; Crowley D; Yang A; McKeon F; Jacks T Cancer Cell; 2005 Apr; 7(4):363-73. PubMed ID: 15837625 [TBL] [Abstract][Full Text] [Related]
30. Transcriptional induction of protein kinase C delta by p53 tumor suppressor in the apoptotic response to DNA damage. Dashzeveg N; Yogosawa S; Yoshida K Cancer Lett; 2016 Apr; 374(1):167-174. PubMed ID: 26884258 [TBL] [Abstract][Full Text] [Related]
31. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432 [TBL] [Abstract][Full Text] [Related]
32. The Rho GTPase RhoE is a p53-regulated candidate tumor suppressor in cancer cells. Zhu Y; Zhou J; Xia H; Chen X; Qiu M; Huang J; Liu S; Tang Q; Lang N; Liu Z; Liu M; Zheng Y; Bi F Int J Oncol; 2014 Mar; 44(3):896-904. PubMed ID: 24399089 [TBL] [Abstract][Full Text] [Related]
33. To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo? Workman P Hum Exp Toxicol; 1995 Feb; 14(2):222-5. PubMed ID: 7779451 [No Abstract] [Full Text] [Related]
34. p53, apoptosis and radiosensitivity--experimental and clinical data. Weber KJ; Wenz F Onkologie; 2002 Apr; 25(2):136-41. PubMed ID: 12006764 [TBL] [Abstract][Full Text] [Related]
35. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Parhar P; Ezer R; Shao Y; Allen JC; Miller DC; Newcomb EW Brain Res Mol Brain Res; 2005 Jun; 137(1-2):98-103. PubMed ID: 15950766 [TBL] [Abstract][Full Text] [Related]
36. AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Thiselton DL; Vladimirov VI; Kuo PH; McClay J; Wormley B; Fanous A; O'Neill FA; Walsh D; Van den Oord EJ; Kendler KS; Riley BP Biol Psychiatry; 2008 Mar; 63(5):449-57. PubMed ID: 17825267 [TBL] [Abstract][Full Text] [Related]
37. [Role of the tumor suppressor ARF in oncogenesis]. Pimkina IuS; Dorosevich AE Arkh Patol; 2009; 71(1):60-3. PubMed ID: 19514363 [TBL] [Abstract][Full Text] [Related]
38. Need for clarification of data in a recent meta-analysis about TP53 codon 72 polymorphism and cancer susceptibility. Lu PH; Wei MX; Li C; Shen W; Chen MB Carcinogenesis; 2011 Mar; 32(3):443; author reply 444. PubMed ID: 21135152 [No Abstract] [Full Text] [Related]
39. Hzf and hCAS/CSE1L: making the right choice in p53-mediated tumour suppression. Ewings KE; Ryan KM Cell Res; 2007 Oct; 17(10):829-31. PubMed ID: 17934491 [No Abstract] [Full Text] [Related]